Souhaitez-vous accéder aux communiqués récents ?

Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in...

Orlando, Fla., June 26, 2017 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) today inducted Carol A. Friesen, FHFMA, into office as Chair of its Board of Directors for the...

NORTHBROOK, Ill., June 26, 2017 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the re-submission of its New Drug Application (NDA) for JATENZO™ (formerly Rextoro™), the Company’s...

DUBLIN, Ireland, June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective...

OTTAWA, June 26, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) ("ABcann" or the "Company") is pleased to announce that it has amended and extended the research contract currently...

SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced...

NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), recapped clinical data from two triple combination therapy trials using TGR-1202 (umbralisib), the Company’s oral,...

Phase 1 results will inform potential Phase 2 studies in patients with fibromyalgia and neuropathic pain, planned to start in 2H17 Study includes single rising dose and multiple rising dose...

Westchester, Ill., June 26, 2017 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) announces a new data service, provided by Med-Metrix, which helps automate portions of the...

MS patients treated with TG-1101 exhibited median B-cell depletion of 99% at week 4 TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months ...